title: A chronic subdural hematoma in a patient receiving combination therapy with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C.
abstract: A 70-year-old man who suffered from chronic hepatitis C was infected with HCV genotype 1 and exhibited a high viral load. He had hypertension and had consumed the equivalent of 50 g of ethanol per day. He was treated with pegylated interferon and ribavirin. After 51 weeks, he developed an unsteady gait while walking and demonstrated Barre's sign on the right foot and a headache. Contrast computed tomography showed a subdural hematoma with a mass effect. The patient was treated with drainage and aspiration surgery via a burr hole. Following the drainage procedure, there were no neurological sequelae. Treatment with pegylated interferon and ribavirin was discontinued. Fortunately, a sustained virological response was achieved.
authors.affiliation: Department of Gastroenterology, Akita University Graduate School of Medicine, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Goto
authors.forename: Shigetoshi
authors.initials: S
authors.lastname: Ohshima
authors.forename: Kouichi
authors.initials: K
authors.lastname: Miura
authors.forename: Tomomi
authors.initials: T
authors.lastname: Shibuya
authors.forename: Wataru
authors.initials: W
authors.lastname: Sato
authors.forename: Takahiro
authors.initials: T
authors.lastname: Dohmen
authors.forename: Kentaro
authors.initials: K
authors.lastname: Kamada
authors.forename: Ryo
authors.initials: R
authors.lastname: Kanata
authors.forename: Toshitaka
authors.initials: T
authors.lastname: Sakai
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Chiba
authors.forename: Yuko
authors.initials: Y
authors.lastname: Sugimoto
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Minami
authors.forename: Hirohide
authors.initials: H
authors.lastname: Ohnishi
mesh_terms: D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D020200:Hematoma, Subdural, Chronic / Q000175:diagnosis / Q000209:etiology* / Q000601:surgery; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects*; D014057:Tomography, X-Ray Computed
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b